Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.10.002Source: DataRank Database

Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2023). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.10)OA: greenTopics (31)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Ajay K. Gopal ORCID,Brian G. Till ORCID,Mazyar Shadman ORCID,Ryan C. Lynch ORCID,Andrew J. Cowan ORCID

Live enrichment

PubMed:37926672 PMC:PMC10841534 OpenAlex:https://openalex.org/W4387745534

National Cancer Institute

Grant: K24CA184039

National Cancer Institute

Grant: P30 CA015704

National Heart, Lung, and Blood Institute

Grant: T32HL007093

National Institutes of Health

Merck Sharp and Dohme United Kingdom

FWCI

2.10

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10841534/pdf/nihms-1938471.pdf

publisherhttps://api.elsevier.com/content/article/PII:S2152265023021456?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2152265023021456?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10841534

Fields of Study

Lymphoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersCAR-T cell therapy researchMedicine

MeSH Terms

RituximabAdultAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFollow-Up StudiesHumansPrednisoneVincristineLymphoma, Large B-Cell, DiffuseAntibodies, Monoclonal, Murine-DerivedB7-H1 AntigenAntibodies, Monoclonal, Humanized

Keywords

MedicinePembrolizumabCHOPOncologyInternal medicineSafety profileAdverse effectLymphomaImmunotherapyCancerPD-L1B-cell LymphomaNon-hodgkin LymphomaImmune Checkpoint Inhibitors

Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up

FAIR Checklist

Authors (15)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)